FDAnews
www.fdanews.com/articles/202923-abivaxs-ulcerative-colitis-drug-shows-promise-in-mid-stage-trial

Abivax’s Ulcerative Colitis Drug Shows Promise in Mid-Stage Trial

May 27, 2021

Abivax said its experimental small-molecule drug, ABX464, demonstrated positive efficacy for patients with moderate-to-severe ulcerative colitis in a phase 2b trial, paving the way for the study to progress to phase 3.

Topline results from 254 participants also indicated the once-daily oral therapy displayed a positive safety profile, the French drugmaker said. A late-stage trial is planned to launch by year’s end.

Abivax is focused on developing immune system modulators for the treatment of chronic inflammatory diseases, viral infections and cancers.

View today's stories